Literature DB >> 6805690

Effect of transdermally administered hyoscine methobromide on nocturnal acid secretion in patients with duodenal ulcer.

R P Walt, C J Kalman, R H Hunt, J J Misiewicz.   

Abstract

Use of anticholinergic drugs in treatment of duodenal ulcers is limited by the side effects of widespread parasympathetic blockade evoked by usual therapeutic doses. A study was conducted into the effectiveness of transdermal delivery of hyoscine methobromide using a new system which releases the drug into the circulation at a controlled rate. In six patients whose duodenal ulcer had healed secretion of acid was measured over two nights, the first on placebo and the second on hyoscine methobromide. All patients responded to the active drug and showed a significant inhibition of acid secretion. Four subjects complained of a dry mouth after overnight treatment with hyoscine methobromide; no other side effects were reported. Transdermal delivery of anticholinergic drugs may be useful in maintenance treatment of duodenal ulcers and further clinical tests are indicated.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6805690      PMCID: PMC1498662          DOI: 10.1136/bmj.284.6331.1736

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


  8 in total

Review 1.  Anticholinergics: do they work in peptic ulcer?

Authors:  K J Ivey
Journal:  Gastroenterology       Date:  1975-01       Impact factor: 22.682

2.  The influence of vagotropic and sympathicotropic stimuli on the secretion of gastric mucin and its fractions in man.

Authors:  G B J GLASS; L J BOYD
Journal:  Am J Dig Dis       Date:  1950-11

3.  Effect of transdermally administered scopolamine in preventing motion sickness.

Authors:  M E McCauley; J W Royal; J E Shaw; L G Schmitt
Journal:  Aviat Space Environ Med       Date:  1979-11

4.  Studies on peptic ulcer disease with special reference to the effect of l-hyoscyamine.

Authors:  A Walan
Journal:  Acta Med Scand Suppl       Date:  1970

5.  Prevention of experimental motion sickness by scopolamine absorbed through the skin.

Authors:  A Graybiel; J Knepton; J Shaw
Journal:  Aviat Space Environ Med       Date:  1976-10

6.  Tri-potassium di-citrato bismuthate: a report of its pharmacological properties and therapeutic efficacy in peptic ulcer.

Authors:  R N Brogden; R M Pinder; P R Sawyer; T M Speight; G S Avery
Journal:  Drugs       Date:  1976-12       Impact factor: 9.546

Review 7.  Carbenoxolone: a review of its pharmacological properties and therapeutic efficacy in peptic ulcer disease.

Authors:  R M Pinder; R N Brogden; P R Sawyer; T M Speight; R Spencer; G S Avery
Journal:  Drugs       Date:  1976       Impact factor: 9.546

8.  Pirenzepine in peptic ulcer. Introduction to clinical trials reports.

Authors:  S M Chierichetti; M Gaetani; G Petrin
Journal:  Scand J Gastroenterol Suppl       Date:  1979
  8 in total
  3 in total

1.  Transdermal scopolamine and gastric acid secretion.

Authors:  K H Antonin; P R Bieck
Journal:  Gut       Date:  1987-12       Impact factor: 23.059

2.  Effects of transdermal scopolamine, alone or in combination with cimetidine, on total 24 hour gastric acid secretion in patients with duodenal ulcer.

Authors:  C T Richardson; M Feldman
Journal:  Gut       Date:  1986-12       Impact factor: 23.059

Review 3.  Transdermal hyoscine (Scopolamine). A preliminary review of its pharmacodynamic properties and therapeutic efficacy.

Authors:  S P Clissold; R C Heel
Journal:  Drugs       Date:  1985-03       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.